Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 16/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TEC | P42680 | 1/20 | 0.36 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
| ▸ | BMX | P51813 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272867 | 1.00 | ABCB1 (0.39) | ABCB1BTKUSP2ALDH1A1CYP1A2 | |
| SCHEMBL25272866 | 1.00 | ABCB1 (0.39) | ABCB1BTKUSP2ALDH1A1CYP1A2 | |
| SCHEMBL30449258 | 0.97 | ABCB1 (0.37) | ABCB1BTKUSP2ALDH1A1CYP1A2 | |
| SCHEMBL25271087 | 0.95 | ABCB1 (0.36) | ABCB1BTKUSP2ALDH1A1CYP1A2 | |
| SCHEMBL25271086 | 0.95 | ABCB1 (0.36) | ABCB1BTKUSP2ALDH1A1CYP1A2 | |
| SCHEMBL25230188 | 0.90 | BTK (0.33) | ABCB1BTKUSP2ALDH1A1CYP1A2 | |
| SCHEMBL25230898 | 0.80 | ABCB1 (0.44) | ABCB1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30449368 | 0.80 | ABCB1 (0.44) | ABCB1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25271223 | 0.80 | ABCB1 (0.44) | ABCB1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30449053 | 0.80 | BTK (0.53) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448523-A1 | MACROCYCLIC BTK INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110970-A1 | MACROCYCLIC BTK INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | ABCB1 1077/4885BTK 1/4885USP2 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.